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The Beta-adrenergic agonist, 
Ractopamine, increases skeletal 
muscle expression of Asparagine 
Synthetase as part of an integrated 
stress response gene program
David Brown1,5, Kevin Ryan1,6, Zoe Daniel1, Molebeledi Mareko1,7, Richard Talbot4, 
Joanna Moreton3, Tom C. B. Giles3, Richard Emes2,3, Charlie Hodgman1, Tim Parr1 & 
John M. Brameld1
Synthetic beta-adrenergic agonists (BA) have broad biomedical and agricultural application for 
increasing lean body mass, yet a poor understanding of the biology underpinning these agents is 
limiting further drug discovery potential. Growing female pigs (77 ± 7 kg) were administered the BA, 
Ractopamine (20 ppm in feed), or the recombinant growth hormone (GH), Reporcin (10 mg/48 hrs 
injected) for 1, 3, 7, 13 (n = 10 per treatment, per time point) or 27 days (n = 15 per treatment). Using 
RNA-sequencing and inferred pathway analysis, we examined temporal changes to the Longissimus 
Dorsi skeletal muscle transcriptome (n = 3 per treatment, per time point) relative to a feed-only control 
cohort. Gene expression changes were affirmed by quantitative-PCR on all samples (n = 164). RNA-
sequencing analysis revealed that BA treatment had greater effects than GH, and that asparagine 
synthetase (Asns) was the 5th most significantly increased gene by BA at day 3. ASNS protein expression 
was dramatically increased by BA treatment at day 7 (p < 0.05). The most significantly increased gene 
at day 3 was activating transcription factor 5 (Atf5), a transcription factor known to regulate ASNS 
gene expression. Gene and protein expression of Atf4, another known regulator of Asns expression, 
was not changed by BA treatment. Expression of more than 20 known Atf4 target genes were increased 
by BA treatment, suggesting that BA treatment induces an integrated stress response (ISR) in skeletal 
muscle of pigs. In support of this, mRNA expression of sestrin-2 (Sesn2) and cyclin-dependant kinase 
1 alpha (Cdkn1a), two key stress-responsive genes and negative regulators of cellular growth, were 
also strongly increased from day 3 of BA treatment. Finally, tRNA charging was the most significantly 
enriched pathway induced by BA treatment, suggesting alterations to the translational capacity/
efficiency of the muscle. BA-mediated changes to the skeletal muscle transcriptome are highly 
indicative of an integrated stress response (ISR), particularly genes relating to amino acid biosynthesis 
and protein translational capacity.
Synthetic beta-adrenergic agonists (BA) have broad biomedical and agricultural application; from combating 
muscle wasting to accelerating the accretion of lean mass in livestock1–3. BA stimulate accretion of myofibrillar 
proteins in adult skeletal muscle by increasing protein synthesis and/or decreasing protein degradation4–6. Despite 
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their broad application and well-documented efficacy, a poor understanding of the intricate biology underpin-
ning the physiological actions of BA is limiting further drug discovery potential in this field.
BA mediate their effects on skeletal muscle via beta-adrenergic receptors (predominantly the beta-2 subtype)1, 
activating the adenylate cyclase pathway and inducing an increase in intracellular cyclic adenosine monophos-
phate (cAMP) concentrations. Elevated cAMP activates Protein Kinase A (PKA)-dependant phosphorylation 
of enzymes such as glycogen phosphorylase, which results in the rapid mobilization of muscle glycogen stores3. 
PKA also phosphorylates the cAMP-Responsive Element Binding Proteins (CREBs, also known as activating 
transcription factors (ATF))7. Given that CREB/ATF transcription factors occupy approximately 20% of human 
protein-coding gene promoters8, it is perhaps unsurprising that BA trigger extensive alterations to the skeletal 
muscle transcriptome9,10. The Protein Kinase B (AKT) – Mechanistic Target of Rapamycin (mTOR) pathway, a 
major regulator of protein synthesis and cellular metabolism11, has been implicated in the muscle sparing and 
muscle hypertrophy effects induced by BA12. Increased calpastatin expression and reduced calpain activity have 
also been reported in BA treated animals4,5,13, which may account for the observed reductions in skeletal muscle 
proteolysis6.
Identifying genes that are involved in the muscle modifying effects of BA could infer novel modes of muscle 
mass regulation, enabling the identification of new strategies to manipulate muscle mass. Two previous studies 
examined time-dependant responses of the skeletal muscle transcriptome to BA administration following 1 and 
4 hours10 or 1 and 10 days9 of administration. These studies revealed impressive alterations in gene expression 
by BA, but the strength of the data set was limited by the use of only 2 time points. We recently14 expanded on 
these studies, employing a pig microarray to analyse temporal changes to the pig skeletal muscle transcriptome 
in response to BA and growth hormone (GH) administration spanning ~4 weeks, using time points at 1, 3, 
7, 13 and 27 days, which, to date, is the most comprehensive data set of its kind. In that study14, we identified 
coordinate increases in expression of mitochondrial phosphoenolpyruvate carboxykinase 2 (PEPCK-M) and 
3-phosphoglycerate dehydrogenase (PHGDH) in response to BA. These enzymes are both involved in amino acid 
biosynthesis and their function in adult skeletal muscle is currently being explored. We attributed the identifi-
cation of these enzymes to the use of such an extensive time course; however, the microarray employed did not 
provide full coverage of the pig transcriptome. Therefore, in line with NC3R guidelines to reduce the number of 
animals used in research15, we performed RNA-sequencing on the same samples14 to obtain better coverage of the 
skeletal muscle transcriptome in response to GH or BA treatment. The aim being to investigate global alterations 
in skeletal muscle gene expression during administration of GH or the synthetic BA, Ractopamine, and thereby 
identify novel molecular events underpinning the “muscle modifying” effects of this anabolic compound. Given 
the increasing use of the pig as a biomedical model for human research16, this study provides biologically relevant 
information to both biomedical and agricultural fields.
Methods
Pig study design. For a full description of the study design, see14 from which the samples used herein were 
generated. The project was approved by The University of Nottingham Ethical Review Committee and conducted 
in accordance with the UK Animals (Scientific Procedures) Act of 1986 (Project License PPL 40/3010). Briefly, 
adult gilts (female pigs) with a mean starting body weight of 77 ± 7 kg were all provided a high quality feed 
(non-pelleted, 16.7% protein finisher feed, 14 MJ/kg; Target Feeds, UK). The BA group received the beta-adr-
energic agonist, Ractopamine (Elanco Animal Health, Grenfield, IN), at 20 ppm in their feed, whereas the GH 
group were administered an intramuscular injection of the recombinant growth hormone, Reporcin (Zamira; 
10 mg/kg/48-hours, GH group) for 1, 3, 7, 13 (n = 10 per treatment per time point) or 27 days (n = 15 per treat-
ment). Treated animals were compared to a control cohort (receiving feed only) at each respective time point. 
After an overnight fast, animals were euthanized by electrical stunning followed by exsanguination. A sample of 
the Longissimus Dorsi (LD) muscle was excised at the 10th rib and RNA extracted as previously described14. LD 
muscle RNA from 3 randomly selected pigs per treatment per time point (n  = 45 pigs) was used for quantitative 
RNA-sequence analyses. Validation of RNA-sequencing data was performed by quantitative-PCR (qPCR) on all 
164 samples.
Preparation of RNA. Total RNA was extracted from 100 mg of frozen LD muscle tissue from all 164 pigs 
using TRIZOL reagent (Invitrogen, Paisley, UK) followed by DNase treatment (Promega, Southampton, UK), 
according to the manufacturer’s instructions. The RNA samples selected for RNA-sequencing were purified using 
the Qiagen miRNeasy kit, by following the manufacturer’s instructions. RNA quantity was measured using a 
Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, US) and RNA integrity number (RIN) was deter-
mined using an Agilent 2100 Bioanalyser (Agilent, Stockport, UK). Samples used for RNA-sequencing had a 
minimum RIN of 7, with an average RIN of 8.2.
RNA-sequencing. RNA sequencing was carried out using the Illumina platform. Sequencing libraries for 
each sample were prepared using the TruSeq RNA Sample Prep Kit-v2 from Illumina (Cambridge UK). Briefly, 
poly(A) RNA was captured from an input of 1 µg of total RNA using the beads provided in the kit, the chemical 
fragmentation of the RNA is included in the elution of the poly(A) RNA from the beads. The fragmented RNA 
was reverse transcribed using a random primer cocktail provided in the kit and SuperScript II (Life Technologies, 
Paisley UK). A double stranded DNA generated from the cDNA was blunt ended before A-tailing and the ligation 
of barcoded adapters. After removing un-ligated adapters the library was subjected to 11 cycles of PCR to increase 
the yield of products.
The final sequencing libraries were assessed using electrophoresis on an Agilent Bioanalyser DNA 1000 chip 
(Agilent, Stockport, UK) to identify the size of the library products; the average library size was 328 ± 8 bases. The 
sequencing library was quantified by qPCR using the KAPA Library Quantification Kits for Illumina platforms 
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(Kapa Biosystems, London, UK); the average concentration of the libraries was 14.2 nM ± 7.7 nM. Balanced 
library pools of 9 samples per pool were prepared and quantified by qPCR.
Sequencing of the libraries was carried out on an Illumina HiSeq 2500 in Rapid output mode using the 
Illumina Truseq Rapid v1 chemistry. The library pools were denatured and loaded at a concentration of 13 pM 
onto the flow cell using the Illumina cBot with the Truseq Rapid PE clustering kit. Libraries were sequenced for 
100 bases paired-end sequencing providing an average of 25 million reads per sample for analysis. Data is availa-
ble at the European Nucleotide Archive (https://www.ebi.ac.uk/ena/) Project PRJEB28262.
Differential gene expression and inferred pathway enrichment analysis. Fastq format reads were 
processed using Trim Galore! to remove adapter sequences and low quality bases (Phred < 20). Trimmed reads 
were mapped to the pig genome Ensembl build (Sscrofa10.2.73, Aug 2011 Ensembl v73) using TopHat v2.0.917 
using the option ‘--no-novel-juncs’ to quantify the reference annotation only. Mapped read counts for each anno-
tated gene were generated using htseq-count (version 0.5.4p3, options --stranded = no –a10)18. Significantly dif-
ferentially expressed genes between control and treated at each time point were identified using EdgeR19, which 
uses empirical Bayes estimation and exact tests based on the negative binomial distribution to identify statistically 
robust differentially expressed genes.
False discovery rate (FDR) was calculated using the Benjamini-Hochberg correction20. Identified differen-
tially expressed genes (FDR corrected p-value < 0.05) were assessed for enrichment of pathways and annota-
tions within these genes. Statistical enrichment was calculated by a right tailed Fisher’s exact test (IPA, QIAGEN 
Redwood City www.qiagen.com/ingenuity). Results were visualised by plotting the enrichment in different 
groups as –log10 p values.
Quantitative PCR validation of mRNA abundance. Transcript abundance of differentially expressed 
genes (identified by RNA-sequencing analysis) was validated by qPCR on all 164 LD muscle samples (control, 
BA and GH treated) using the standard curve method and expression values were normalized to total cDNA in 
the PCR reaction using the established oligreen method as previously described14. The inclusion of GH-treated 
samples in the gene expression validation permitted comparison of effects between BA and GH. Sample treatment 
and time allocations were blinded to the researcher conducting the qPCR. All oligonucleotide primer sequences 
are displayed in Table 1.
Western blotting. Protein was extracted from 100 mg LD muscle by homogenization in extraction buffer 
containing 150 mM NaCl, 50 mM HEPES, 2.5 mM EDTA, 10% Glycerol, 1% Triton, and protease and phosphatase 
inhibitor cocktails (Roche, UK). A sample of whole homogenate and supernatant (generated by centrifugation 
at ~15,000 g for 10 minutes) were transferred to an equal volume of 2x Laemmli loading buffer. Constant protein 
(50 µg for LD muscle samples, 5 µg for muscle cells) was loaded and separated on a 4–15% precast acrylamide 
gel (Criterion TGX, BioRad) and wet transferred to nitrocellulose membranes, with ponceau staining used to 
confirm the equal loading of protein. Whole homogenate samples were probed using anti-ATF4 (Cell Signaling; 
#11815) and supernatant samples were probed using anti-ASNS (Atlas Antibodies; HPA029318) followed by 
anti-rabbit secondary (GE Healthcare Life Science). Bands were visualized using ECL detection reagent (GE 
Healthcare Life Science). Densitometry of band intensity was conducted to determine protein expression levels.
Porcine myoblast cells for ASNS and ATF4 antibody validation. Porcine myogenic precursor cells 
were a kind gift from Dr Paul Loughna (University of Nottingham, UK) and were originally isolated from the 
Gene ID Forward Reverse
Arg2 ATACAGGGTTGCTCTCAGCATTG CGTAGCCTTGGCCTCTTCCT
Asns GTGTTCAGAAGCTAAAGGTCTCGTT GGCGACTTTGCCATTTGG
Ass1 TTGGAGAATGCCCGAGTTCTA GTGTTGCTTCGCGTACTCCAT
Atf4 TGGCCATCTCCCAGAAAGTT GGGAAGAGTTTGCAAGAACGTAA
Atf5 TGCCCTCTCCGCAACTTC CATCTGTTCCAACTCCTTCTTGAG
Atf6A CGTATTCTCCAGGGTGCTCTAGAA ACTCCCTGAGTTCCTGCTGATACT
Atf6B CCGAAGGGACCACCTGTTG GCCATGGCAGGCATCAC
Cdkn1A TGGAACTTCGACTTCATCACTGA CAAGGCCTCGCACACGTT
Cebpg GCTGAACGGGCTAACTGTCACT GCTGCGGAACCTGCTGTAAG
Ern1 CCTGACGAAACTTCCCTTTACG CATGTAGAGAATTCCATCCGAACTT
Gadd153 GAAATGAGGAGGAGTCAAAAACCTT GCTCTGGGAGGTGTGTGTGA
Gadd45A CAGAAGACTGAAAGGATGGATAAGG GGTGATTGTGCGCTGACTCA
Sars GATGATGGACAAGGTGGAGTTTG AGTTCTCCAGGATGGCACAGA
Sesn2 AAGACCACCCGAAGAATGTACAA GCAAGTTCACGTGGACCTTCTC
Slc3a2 TCAGCGAGGATAGGCTCTTGA GGACAGGTACGAGCTAGTTAACAACA
Slc7a1 GGTGGTCACGGCCATCAT GGAAGGGCACCTTGAAGGA
Slc1a5 CAAGGAGGTGCTCGATTCGT TTGAATGGCCTCTCCGAGTAG
Xbp1 GAATGGCCCTTTATCATTTCTCTTC AAGCAAACTAAAGGACCTAAAATCAGA
Table 1. Oligonucleotide sequences used for quantitative PCR.
www.nature.com/scientificreports/
4SCientifiC REPORTS |         (2018) 8:15915  | DOI:10.1038/s41598-018-34315-9
Semimembranosus muscle as previously described21. Confluent porcine cells were cultured in Dulbecco’s Modified 
Eagles Medium (DMEM) with 20% fetal calf serum, 100 units/ml penicillin, 0.1 mg/ml streptomycin and 2.5 µg/
ml Amphotericin B. Cells were treated with 250 nM Thapsigargin for 8 hours to induce expression of endoplasmic 
reticulum stress proteins. All cell culture reagents were purchased from Sigma Aldrich UK. Cells were harvested 
directly into 1x Laemmli loading buffer including protease and phosphatase inhibitors (Roche) and stored at 
−20C until use. Samples were used for western blotting as described above.
Statistical analysis. Statistical analyses on qPCR and Western blotting data were performed using Genstat 
(13th–15th edition). Changes in relative mRNA transcript abundance were assessed for significant treatment (BA, 
GH or control), time (1, 3, 7, 13 and 27 days) and treatment x time interactions using a two-way analysis of var-
iance (ANOVA). Post-hoc Dunnett’s tests were performed to compare BA and GH group means to the control 
mean, whereas Bonferroni tests were used for significant time x treatment interactions. Significance was accepted 
if p < 0.05. Relative mRNA expression is presented as mean ± standard error of the mean (SEM).
Results
Ractopamine increases expression of tRNA charging and amino acid biosynthesis genes. RNA-
sequencing analysis revealed that BA treatment had greater effects than GH and inferred pathway enrichment 
analysis (IPA) revealed that four of the top ten enriched pathways for BA were involved in tRNA charging, serine 
biosynthesis or arginine metabolism (Fig. 1A). Of the top ten enriched pathways for BA, none displayed signif-
icant enrichment prior to day 3. The most significantly enriched pathway for BA treatment was tRNA charging 
(Fig. 1A), with several aminoacyl-tRNA synthetase genes (Aars, Iars, Tars, Wars, Gars, Sars) being strongly up reg-
ulated, particularly at day 3 (see heat map in Fig. 1B). The serine biosynthesis pathway genes (Phgdh, Psat1, Psph) 
formed the second most significantly enriched pathway, which again were particularly evident from day 3 onwards 
(Fig. 1A,B) and agreed with our previous microarray analyses14 where we saw increases in Phgdh and Pck2 mRNA 
and protein in these same animals. Enriched genes in the Calcium Signalling pathway mainly related to struc-
tural and contractile proteins in muscle (e.g. Actc1 and Myl4 – Fig. 1B and Supplementary Table 1), with many of 
Figure 1. Inferred pathway enrichment analysis for BA treated animals. (A) Enriched pathways are ranked 
from left-to-right by mean –log10 p value. The 3 black lines from bottom-to-top depict p values of 0.05, 0.01 and 
0.001 respectively. Colours of the bar chart are orange (day 1) olive green (day 3), bright green (day 7), blue (day 
13) and purple (day 27). (B) Heat map to show top changing genes identified by inferred pathway analysis. Red 
and green respectively indicate treatment-induced increases and decreases in gene expression relative to that 
of the control animals. The intensity of red and green denote the significance (−log10 p value) of the change in 
expression (see colour key). Each column represents a time point (in days) following the initiation of treatment. 
n = 3 per treatment per time point.
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those down-regulated by BA being associated with slow muscle fibres (e.g. Myh7, Tnnt1, Tnnc1 and Tnnt2). Genes 
involved in the urea cycle (Arg2 and Ass1) and arginine degradation (Arg2 and Pycr1) also displayed significant 
enrichment from day 3 onwards. These analyses therefore indicated that day 3 was a time point whereby metabolic 
adaptations to the muscle-modifying drug, Ractopamine, were most pertinent.
Ractopamine increases skeletal muscle expression of Asparagine Synthetase (ASNS). IPA 
analysis (Fig. 1), as well as our previous microarray analyses14, directed our interest to genes increasing in expres-
sion at day 3 of BA treatment. A list of genes that showed a greater than 3-fold increase in expression by BA 
treatment at day 3 (p < 0.05) are displayed in Fig. 2A and affirm the results of the IPA analysis. The 24 genes high-
lighted in bold (Fig. 2A) are largely involved in amino acid biosynthesis and transport as well as protein trans-
lation. Ingenuity Knowledge Base analysis, together with searching the published literature, indicated that these 
genes are highly indicative of an integrated stress response (ISR)22. Further indication of an ISR is that the most 
significantly up regulated gene at day 3 was activating transcription factor 5 (Atf5), which binds to promoters of 
integrated stress responsive genes23.
The increased Asns transcript abundance (identified by RNA-sequencing analysis) at day three was particularly 
noteworthy given that this enzyme typically displays very low basal expression in most tissues24. Confirmation of 
Asns mRNA expression by qPCR revealed a potent increase in mRNA abundance in response to BA treatment, 
peaking at day 3 but remaining elevated above control levels throughout the entirety of the 27-day study period 
(treatment x time interaction: p < 0.001; Fig. 2B). Furthermore, western blot analysis of ASNS protein expression 
at day 7 (the time point following the peak in mRNA abundance) showed induction of ASNS protein in skeletal 
muscle of pigs treated with Ractopamine (Fig. 2C,D), although the magnitude of response was quite variable 
between individual pigs as is reflected in the larger error bar (SEM). Unlike BA treatment, GH did not increase 
ASNS protein expression on day 7 (Fig. 2C), but it did induce a transient increase in Asns mRNA expression on 
days 1 and 3 (Fig. 2B), with expression reducing to control levels thereafter.
Ractopamine perturbs metabolic homeostasis. Expression levels of a subset of genes displayed in 
Fig. 2A were validated by qPCR (Fig. 3A–H) to confirm the widespread increase in expression of genes involved 
in an ISR and metabolic homeostasis. Messenger RNA abundance of solute carrier genes (Slc3a2, Slc7a1, Slc1a5), 
which are involved in amino acid transport, were increased by BA treatment (Fig. 3A–C; see figure legend for 
stats). The day 3 increase in expression of seven tRNA synthetases was affirmed by measuring Sars mRNA 
abundance (Fig. 3D), which displayed an obvious increase in expression specifically at day 3 with BA treatment 
(treatment x time interaction: p < 0.005). Arginase 2 (Arg2) and argininosuccinate synthase 1 (Ass1), which are 
Figure 2. Identification of Asparagine Synthetase (Asns) as a novel BA responsive gene. (A) Genes displaying 
>3-fold increase in expression with BA treatment at day 3 (relative to control) measured by RNA-sequencing. 
Genes ranked by significance (p < 0.05). (B) qPCR validation of Asns expression in all samples (Control, BA 
and GH; total n = 164). *p < 0.001 for time x treatment interaction (see Supplementary Table 2 for post hoc 
Bonferroni test comparisons). (C) Representative image of western blot for ASNS in control, BA and GH 
treated LD muscles at day 7 (see supplementary Figure 1 for full blot and gel). (D) Quantitation of ASNS protein 
abundance at day 7 from western blot. #p < 0.05 (ANOVA).
www.nature.com/scientificreports/
6SCientifiC REPORTS |         (2018) 8:15915  | DOI:10.1038/s41598-018-34315-9
involved in arginine metabolism, also displayed increased mRNA expression with BA treatment (treatment x 
time interaction of p < 0.001 and p < 0.005, respectively; Fig. 3E,F). The stress responsive genes, sestrin-2 (Sesn2) 
and cyclin-dependant kinase 1 alpha (Cdkn1a), which are both negative regulators of cellular growth, were 
also strongly increased by BA treatment (treatment x time interaction of p < 0.001 and p < 0.005, respectively; 
Fig. 3G,H). As observed for Asns mRNA expression (Fig. 2B), GH induced a transient increase in mRNA, mainly 
on day 1, for the majority of these genes (all except Ass1), with expression reducing to control levels thereafter 
(Fig. 3A–H).
Ractopamine does not alter expression of Atf4 but it does increase Atf5 mRNA. The BA respon-
sive genes identified herein are all highly suggestive of a perturbation to metabolic homeostasis, particularly 
amino acid metabolism and protein translation. Ingenuity Knowledge Base analysis, together with searching the 
published literature, indicated that more than 20 of the genes increased by BA treatment at day 3 are documented 
targets of activating transcription factor 4 (Atf4), a central component of the integrated stress response (ISR)22. 
Messenger RNA expression of Atf4 showed little effect of treatment (Fig. 4A), which is perhaps unsurprising 
because ATF4 protein expression is largely regulated post-transcriptionally. Due to the well-known difficulties 
associated with measuring ATF4 protein expression in vivo, we first generated an ATF4 positive control by treat-
ing primary porcine myoblasts with an ATF4-inducing compound, thapsigargin. Using protein from these cells 
enabled us to confirm that the antibody used herein was capable of detecting porcine ATF4 in skeletal muscle 
cells, as shown in Fig. 4B. Next, we probed pig muscle samples from days 1 and 3 with this ATF4 antibody. These 
time points were chosen because they preceded and coincided, respectively, with the peak in mRNA expression 
of the suspected ATF4 target genes. We were unable to confidently detect a quantifiable band representing ATF4 
(Fig. 4C), most likely due to a very low abundance of the protein. We conclude that, using the methods employed 
herein, ATF4 protein expression was probably not changed by BA treatment.
Interestingly, RNA-sequencing analysis identified activating transcription factor 5 (Atf5) as the most signif-
icantly increased gene on day 3 (Fig. 2A). This was confirmed by qPCR, which revealed an expression profile 
similar to genes in Fig. 3, with the increased expression peaking at day 3 (treatment effect: p < 0.01). However, 
commercially available antibodies against ATF5 were unable to detect porcine ATF5 (data not included). 
Expression of CCAAT/enhancer binding protein gamma (Cebpg) mRNA, a known co-factor of activating 
Figure 3. Validation of amino acid transport, amino acid biosynthesis and tRNA charging gene expression. 
Messenger RNA expression of the following genes were validated by qPCR on all 164 samples (A) solute carrier 
family 3 member 2, (B) solute carrier family 7 member 1, (C) solute carrier family 1 member 5, (D) seryl-tRNA 
synthetase, (E) arginase 2, (F), argininosuccinate synthetase 1, (G) sestrin-2 and (H) cyclin-dependent kinase 
inhibitor 1A. *Indicates a treatment-time interaction with p < 0.001, $indicates a treatment-time interaction 
with p < 0.005, ^indicates a treatment effect with p < 0.01, &indicates a treatment effect with p < 0.05, b indicates 
a significant Dunnetts test with p < 0.01 for BA vs. control (GH vs. control  = NS). For genes with significant 
interactions, see Supplementary Table 2 for post hoc Bonferroni test comparisons. Data are mean ± SEM. Days 
1, 3, 7 and 13 have n = 10 whilst day 27 has n = 15. White bars = control, black bars = GH (growth hormone), 
grey bars = BA (beta-adrenergic agonist).
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transcription factors, was also increased by BA treatment (treatment effect: p < 0.05); whereas expression of Atf6 
and other known endoplasmic reticulum stress-response genes, including Gadd45a, Gadd153, Xbp1, and Ern1, 
were not significantly altered by BA treatment (p > 0.05; Supplementary Fig. 4A–F).
Discussion
In line with NC3R guidelines to reduce the use of animals15, we used samples generated by a previously published 
animal trial14 to conduct RNA sequencing and inferred pathway enrichment analysis (IPA), enabling us to obtain 
better coverage of the skeletal muscle transcriptome in pigs treated with BA or GH. In doing so, we showed that 
BA treatment had greater effects than GH and identified novel biological events associated with BA treatment. 
Identifying mechanisms underpinning the actions of anabolic agents, such as BA, is crucial for the development 
of novel muscle anabolic agents for use in livestock production and for the treatment of muscle wasting diseases.
Asparagine synthetase (ASNS) induction by BA treatment. We identified the induction of the 
asparagine synthetase (ASNS) protein in skeletal muscle of pigs administered with a BA, which was not identified 
in the previous report using these samples14. With the exception of the pancreas, basal expression of Asns is typi-
cally very low in all tissues24, as was evident in skeletal muscle herein. Expression of Asns is often associated with 
amino acid limitation24. ASNS converts aspartate and glutamine to asparagine and glutamate24, with the major-
ity of newly synthesized asparagine being utilized for protein synthesis25. In cultured cells, knockdown of Asns 
expression or deprivation of asparagine causes impaired growth26. Whether ASNS expression per se can influence 
the protein synthetic capacity of skeletal muscle warrants further investigation, but falls outside the scope of this 
investigation. The increased ASNS protein expression might contribute to the increased skeletal muscle protein 
synthesis that is often reported during treatment with BA1,4. Alternatively, the BA-mediated induction of ASNS 
might occur in response to amino acid limitation within the skeletal muscle, perhaps caused by an increased reli-
ance on asparagine or other conditionally essential amino acids. Fast-growing poultry are often fed diets high in 
Figure 4. Expression of ATF4 is not altered by BA treatment but Atf5 mRNA is increased. (A) mRNA 
abundance of activating transcription factor 4. (B) Validation of anti-ATF4 antibody to detect ATF4 from 
protein extracted from cultured porcine muscle cells treated with or without thapsigargin (TG) - see 
supplementary figure 2 for full blot and gel. (C) Representative western blots attempting to detect ATF4 
protein in muscle samples from BA, control or GH treated pigs (see supplementary Figure 3 for full blots). 
(D) qPCR validation of activating transcription factor 5 gene expression. (E) CCAAT/enhancer binding 
protein gamma mRNA abundance measured by qPCR. ^indicates a treatment effect with p < 0.01, &indicates 
a treatment effect with p < 0.05, aindicates a significant Dunnetts test with p < 0.05 for BA vs. control (GH vs. 
control = NS), bindicates a significant Dunnetts test with p < 0.01 for BA vs. control (GH vs. control = NS). Data 
is mean ± SEM. Days 1, 3, 7 and 13 have n = 10 whilst day 27 has n = 15. White bars = control, black bars = GH 
(growth hormone), grey bars = BA (beta-adrenergic agonist).
www.nature.com/scientificreports/
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conditionally essential amino acids because endogenous synthesis of these amino acids is thought to become rate 
limiting during rapid growth27. It would be interesting to examine whether supplementation with conditionally 
essential amino acids would ablate the BA-mediated induction of ASNS expression and whether such a strategy 
would improve the growth response of pigs fed a BA. The implication of enhancing BA-mediated growth in pigs 
would be substantial in the effort to avoid a global food security crisis by 20503,28.
Altered expression of ASNS was not identified by previous BA transcriptomic studies in rodents9,10. 
Differences in inter-species metabolic stability29,30 may cause transcriptomic responses controlling amino acid 
metabolism to differ between large mammals and small rodents9,10.
Activating transcription factors (ATF4 and ATF5). Perhaps the most well studied mechanism con-
trolling Asns gene expression is the composite CCAAT/enhancer-binding protein (CEBP)-activating transcrip-
tion factor (ATF) response element (CARE) located in the Asns promoter, which is aptly bound by ATF-CEBP 
heterodimers. The RNA-sequencing analysis identified Atf5 as the most significantly up regulated gene at day 3 of 
BA treatment (which was not reported in our previous publication using these samples14), drawing our attention 
to this as a potential mechanism for the increased Asns expression. Over-expression of ATF4 or ATF5 (which 
have high sequence similarity31) has been shown to increase Asns promoter activity31–34. Protein expression of 
ATF4 and ATF5 is post-transcriptionally controlled by the phosphorylated form of elongation initiation factor 2 
(p-eIF2)24. The BA-mediated increase in Atf5 mRNA expression was confirmed by qPCR but commercially avail-
able antibodies could not detect porcine ATF5 protein (data not shown). There was little effect of BA treatment 
on Atf4 mRNA expression, and whilst we could measure ATF4 protein in cultured porcine myoblasts, we were 
unable to confidently detect ATF4 protein in pig skeletal muscle. The short half-life of ATF4 (~30 minutes)35, and 
the non-pathological setting in which we were examining its expression, likely made ATF4 protein abundance 
difficult to determine. ATF4 has recently been shown to be regulated by phosphorylation36, but we were unable to 
measure phospho-ATF4, so cannot rule out that BA-induced effects could potentially be via phosphorylation of 
ATF4. Whilst we were unable to measure changes in ATF4 protein expression, the sheer number of known ATF4 
target genes (Asns34,37, Phgdh37,38, Psat138, Psph38, Pck239,40, Gpt240, Wars37, Sars37, Gars37, Tars41, Slc7a137,41, Slc3a237, 
Fgf2142,43, Sesn240,44, Cdkn1a45, Chac140, Atf540 and Cebpg40) that displayed a >3-fold increase in expression by BA 
treatment at day 3 is highly suggestive of ATF involvement in this BA-mediated integrated stress response.
Ractopamine increases skeletal muscle expression of aminoacyl-tRNA synthetase genes. The 
most significantly enriched pathway during BA treatment was tRNA charging. A strong increase in expression of six 
aminoacyl-tRNA synthetases (Aars, Gars, Iars, Sars, Tars, Wars, Yars) on day 3, accounted for this strong pathway 
enrichment. Aminoacyl-tRNA synthetases (ARS) catalyse the attachment of specific amino acids to their respective 
tRNA, thus regulating both the protein synthetic capacity of the cell and the accuracy of protein assembly46. Elevated 
expression of ARS has been documented previously in rapidly proliferating cell types that exhibit augmented rates 
of protein synthesis, such as cancer cells46,47. It remains unknown, however, whether increased expression of ARS 
drives protein synthesis or whether ARS expression is dictated by the protein synthetic demand of the cell46. BA are 
well known to stimulate changes in skeletal muscle protein metabolism4, but a role for differential ARS expression 
during increased myofibrillar protein accretion has yet to be investigated. Previous transcriptomics studies failed to 
identify this co-ordinated increase in expression of multiple ARS genes by BA treatment9,10, possibly because these 
changes peaked at a time point (day 3) not used in any of these previous studies9,10.
BA mediated increased mRNA expression of Sestrin-2 and Cdkn1a. Sestrin-2 (Sesn2) and 
cyclin-dependent kinase inhibitor 1A (Cdkn1a) mRNA expression were both increased by BA treatment. SESN2 
is an inhibitor of mTOR-mediated cell growth44,48,49, while CDKN1A is an inhibitor of the cyclin dependant 
kinases that drive cell proliferation50. Transcriptomic studies in rodents have previously shown increased Cdkn1a 
mRNA expression with BA treatment, but these studies did not identify changes in Sesn2 expression9,10. The 
sustained increase in transcript abundance of Sesn2 and Cdkn1a is highly indicative of cellular stress, inhibi-
tion of growth and cell survival45,48,49. This is somewhat counterintuitive following administration of a widely 
reported “anabolic” agent and therefore might present a previously unrecognised negative feedback mechanism 
to prevent unsustainable growth. Sesn2 and Cdkn1a genes are also transcriptionally induced during amino acid 
deprivation40,45.
Conclusion
The BA-mediated increase in expression of ASNS (mRNA and protein) and a concomitant increase in mRNA 
expression of several tRNA-synthetases, Sesn2 and Cdkn1a, is highly indicative of a perturbation to metabolic 
homeostasis (i.e. an integrated stress response), particularly relating to amino acid biosynthesis and protein trans-
lational capacity. On-going work is examining the role of these genes in the regulation of muscle mass. Hence, 
this re-analysis of the muscle transcriptomic response to anabolic agents (BA and GH) using an improved meth-
odology (RNA sequencing) has enhanced the transcriptome coverage and identified a number of BA-responsive 
genes not previously identified using microarray, suggesting that an integrated stress response is a potential novel 
mechanism for BA-induced muscle growth.
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